Champions Oncology (CSBR) Retained Earnings (2011 - 2026)
Champions Oncology (CSBR) recorded quarterly Retained Earnings of -$80.4 million in Q1 2026, little changed quarter-over-quarter from -$80.1 million in Q4 2025, and down 2.94% on a YoY basis from -$82.8 million in Q1 2025.
Champions Oncology (CSBR) Retained Earnings (2011 - 2026) Analysis & Trends
Champions Oncology's Retained Earnings history runs 16 years deep, the most recent figure standing at -$80.4 million for Q1 2026.
- In Q1 2026, Retained Earnings fell 2.94% year-over-year to -$80.4 million; the TTM figure through Jan 2026 stood at -$80.4 million (down 2.94% YoY), while the FY2025 annual figure was -$79.9 million, up 5.56% from the prior year.
- Retained Earnings was -$80.4 million for Q1 2026 at Champions Oncology, roughly flat from -$80.1 million in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of -$71.6 million in Q1 2022 to a low of -$84.6 million in Q2 2024.
- Historically, Retained Earnings has averaged -$78.6 million across 5 years, with a median of -$79.9 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Retained Earnings decreased 13.33% in 2023, then grew 7.56% in 2025.
- A 5-year view of Retained Earnings shows it stood at -$72.3 million in 2022, then slipped by 13.33% to -$82.0 million in 2023, then decreased by 0.79% to -$82.6 million in 2024, then rose by 3.0% to -$80.1 million in 2025, then slipped by 0.35% to -$80.4 million in 2026.
- The last three Retained Earnings figures came in at -$80.4 million (Q1 2026), -$80.1 million (Q4 2025), and -$80.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | -153.89 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -211.85 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 1.00 Bn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -279.00 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 130.89 Mn |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | -1.88 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 14.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | -838.07 Mn |
| 10 | Champions Oncology | 78.46 Mn | 71.46 Mn | 13.89 Mn | -80.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -80.40 Mn |
| Oct 31, 2025 | -80.12 Mn |
| Jul 31, 2025 | -80.36 Mn |
| Apr 30, 2025 | -79.89 Mn |
| Jan 31, 2025 | -78.10 Mn |
| Oct 31, 2024 | -82.60 Mn |
| Jul 31, 2024 | -83.30 Mn |
| Apr 30, 2024 | -84.59 Mn |
| Jan 31, 2024 | -84.48 Mn |
| Oct 31, 2023 | -81.95 Mn |
| Jul 31, 2023 | -79.90 Mn |
| Apr 30, 2023 | -77.32 Mn |
| Jan 31, 2023 | -74.80 Mn |
| Oct 31, 2022 | -72.32 Mn |
| Jul 31, 2022 | -72.30 Mn |
| Apr 30, 2022 | -71.98 Mn |
| Jan 31, 2022 | -71.60 Mn |
| Oct 31, 2021 | -72.43 Mn |
| Jul 31, 2021 | -72.70 Mn |
| Apr 30, 2021 | -72.53 Mn |